Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
0(0%)
Results Posted
33%(4 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_3
6
43%
Ph phase_1
5
36%
Ph phase_2
2
14%

Phase Distribution

5

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
5(38.5%)
Phase 2Efficacy & side effects
2(15.4%)
Phase 3Large-scale testing
6(46.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

92.3%

12 of 13 finished

Non-Completion Rate

7.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(12)
Terminated(1)
Other(1)

Detailed Status

Completed12
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
92.3%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (38.5%)
Phase 22 (15.4%)
Phase 36 (46.2%)

Trials by Status

unknown17%
completed1286%
terminated17%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_2

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

NCT03395392
completed

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

NCT04432688
unknownphase_3

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

NCT03396068
terminatedphase_3

A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

NCT04383691
completedphase_2

NRX101 Glx Biomarker Validation Study

NCT03402152
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT03395392Phase 2

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Completed
NCT04432688

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

Completed
NCT03396068Phase 3

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Unknown
NCT04383691Phase 3

A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

Terminated
NCT03402152Phase 2

NRX101 Glx Biomarker Validation Study

Completed
NCT00641745Phase 3

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

Completed
NCT01143090Phase 3

A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

Completed
NCT00549718Phase 3

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Completed
NCT01143077Phase 3

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Completed
NCT01082276Phase 1

Rifampin Drug-Drug Interaction Study With Lurasidone HCl

Completed
NCT01074632Phase 1

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

Completed
NCT01082263Phase 1

Midazolam Drug-Drug Interaction Study With Lurasidone HCl

Completed
NCT01074073Phase 1

Lithium Drug-Drug Interaction Study With Lurasidone HCl

Completed
NCT01082250Phase 1

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14